Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: SYSA1901|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Docetaxel
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.